Imjudo® (tremelimumab-actl) – New drug approval
October 24, 2022 - AstraZeneca announced the FDA approval of Imjudo (tremelimumab-actl), in combination with Imfinzi® (durvalumab) for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC).
Download PDF
